Chambers-Grundy Center for Transformative Neuroscience News
The Chambers-Grundy Center for Transformative Neuroscience provides an academic platform for research and learning opportunities regarding the study of drug development for Alzheimer's disease and other brain disorders. It includes a clinical trials observatory for tracking new treatments, trial designs, and biomarkers in clinical trials for neurodegenerative disorders.
Current Center for Transformative Neuroscience News
The longtime UNLV researcher on youthful curiosity, the brain, and sports.
The Chambers-Grundy Center for Transformative Neuroscience will advance research and the science of treatment for Alzheimer’s and other neurological disorders.
UNLV’s new Department of Brain Health leads interdisciplinary effort to answer tough questions about traumatic brain injury.
Lou Ruvo Center for Brain Health neurologist Dr. Jeffrey Cummings joins UNLV to help launch new program that will be crucial for an aging state population.
Center for Transformative Neuroscience In The News
Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the formation of a Scientific Advisory Board comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH.
Optimistic about the drug’s efficacy, the company has initiated its submission for accelerated FDA approval.
A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for Alzheimer’s disease recently granted accelerated approval by the U.S. Food and Drug Administration (FDA).